INNATE PHARMA Aktie [WKN DE: A0LCUJ / ISIN: FR0010331421]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu INNATE PHARMA SA

20.11.24		Innate Pharma Releases Its 2025 Financial Calendar (Businesswire)
19.11.24		Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 (Businesswire)
13.11.24		Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results (Businesswire)
08.11.24		Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024 (Businesswire)
07.11.24		Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates (Businesswire)
29.10.24		Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Businesswire)
14.10.24		Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board (Businesswire)
30.09.24		Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 (Businesswire)
23.09.24		Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors (Businesswire)
12.09.24		Innate Pharma Reports First Half 2024 Business Update and Financial Results (Businesswire)
09.09.24		Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 (Businesswire)
05.09.24		Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update (Businesswire)
04.09.24		Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
01.08.24		Innate Pharma Announces Its Participation in Upcoming Investor Conference (Businesswire)
25.07.24		Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024 (Businesswire)
18.06.24		Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024 (Businesswire)
17.06.24		Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial (Businesswire)
04.06.24		Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides (Businesswire)
28.05.24		Innate Pharma Announces Its Participation in Upcoming Investor Conferences (Businesswire)
24.05.24		Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting (Businesswire)
23.05.24		Outcome of Innate Pharma’s 2024 Annual General Meeting (Businesswire)
21.05.24		Innate Pharma: Clarification Regarding SAR443579 Designation (Businesswire)
15.05.24		Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress (Businesswire)
14.05.24		Innate Pharma Reports First Quarter 2024 Business Update and Financial Results (Businesswire)
07.05.24		Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update (Businesswire)
15.04.24		Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients (Businesswire)
15.04.24		Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 (Businesswire)
10.04.24		Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate (Businesswire)
09.04.24		Innate Pharma Announces Its Participation in Upcoming Investor Conference (Businesswire)
05.04.24		Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F (Businesswire)
21.03.24		Innate Pharma Reports Full Year 2023 Financial Results and Business Update (Businesswire)
19.03.24		Innate Pharma Announces Its Participation to Upcoming Investor Conference (Businesswire)
14.03.24		Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results (Businesswire)
06.03.24		Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024 (Businesswire)
06.03.24		Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma (Businesswire)
21.02.24		Innate Pharma Announces Its Participation to Upcoming Investor Conference (Businesswire)
12.01.24		Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024 (Businesswire)
04.01.24		Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program (Businesswire)
04.01.24		Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board (Businesswire)
19.12.23		Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi (Businesswire)
11.12.23		Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023 (Businesswire)
10.12.23		Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 (Businesswire)
27.11.23		Innate Pharma to Host Virtual KOL Event on Lacutamab (Businesswire)
14.11.23		Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update (Businesswire)
07.11.23		Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update (Businesswire)
03.11.23		Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 (Businesswire)
27.10.23		Innate Pharma Announces Its Participation to Upcoming Investor Conferences (Businesswire)
19.10.23		Innate Pharma 2024 Financial Calendar (Businesswire)
16.10.23		Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 (Businesswire)
09.10.23		Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023 (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Ripple explodiert – Jetzt investieren und Millionär werden?

Diese Aktien befinden sich Q3 2024 im Portfolio von Warren Buffett

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

thyssenkrupp-Aktie zieht dennoch an: thyssenkrupp mit weiterem Milliardenverlust

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.11.2024 20:15
Kaufwert:	EUR
	Hinzufügen Speichern